Clinical Observation of Lamivudine for Decompensated Cirrhosis Resulting from Chronic Hepatitis B

Objective To evaluate the clinical effect of Lamivudine for decompensated cirrhosis resulting from chronic hepatitis B. Methods 50 patients with decomprnsated cirrhosis were randomized into treatment group(25 cases) and control group(25 cases). The basic therapy of two groups was same. Treatment group was given the same basic therapy and Lamivudine 100 mg orally once daily for 1 month. Clinical manifestation, Child-pugh score, the variety of serum total bilirubin and albumin were observed. Results The clinical manifestations were improved in two groups after 4 weeks of treatment. Improvement rates of Lamivudine treatment group were higer than those of control group (84% VS 60%, P 0.05). The decrease in the Child-pugh score of treatment group was more significant than that of control group(2.92±1.15 VS 1.72±1.06, P 0.05). The decrease in serum total bilirubin of treatment group was more significant than that of control group(28.91±22.13μmol/L VS 12.23±29.74μmol/L, P 0.05).44% treatment group patient's HBV DNA became negative after 4 weeks' treatment,and it had significant difference between control group(0%)( P 0.05). There were no significant side-effects in two groups after treatment. Conclusion Lamivudine treatment is beneficial and safe in patients with decompensated HBV related cirrhosis, but the long-term benefits remain uncertain.